Hyderabad, India and Princeton, NJ, USA. September 9, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. market.
“The launch of Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to our Pain/ Analgesics portfolio of OTC products, and represents our continued commitment to the Private Label OTC space,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. “We are pleased to partner with Encube Ethicals to bring this product to market for the benefit of consumers.”
Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is used for the temporary relief of arthritis pain ONLY in the following areas:
Ÿ hand, wrist, elbow (upper body areas)
Ÿ foot, ankle, knee (lower body areas)
Voltaren® Arthritis Pain brand had total U.S. retail sales of approximately $44 million since launch in May 2020 according to IRI*.
Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), will soon be available in multiple pack sizes to allow consumers a variety of purchasing options.
Voltaren® is a trademark of Novartis Corporation.
*IRI POS TOTAL US – MULO Period ending August 9, 2020
RDY-0820-OTC
